Celsion: Q3 Earnings Insights

Shares of Celsion CLSN remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 32.00% over the past year to ($0.17), which missed the estimate of ($0.13).

Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Celsion hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 16, 2020

Time: 11:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/n6e4r5nw

Price Action

Company's 52-week high was at $6.50

52-week low: $0.43

Price action over last quarter: down 51.53%

Company Overview

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.